Cost analysis of a disease management programme for adult Medicaid clients with schizophrenia

Grant H. Skrepnek, Edward P. Armstrong, Katie Brookler, John Roper, Beth E. Martin, Laurel Karabatsos, Christy Hunter

Research output: Contribution to journalArticlepeer-review

Abstract

This investigation assessed changes in direct medical costs, from the perspective of a public payer, associated with a comprehensive, field-based disease management programme for adult Medicaid clients with schizophrenia in the US State of Colorado. A propensity score-matching algorithm was employed in this retrospective analysis owing to the inherent non-randomisation of enrollees. Of the 126 clients initially enrolled, 73 (58%) remained within the programme continuously for 6-12 months. These participants were associated with 30% lower overall per member per month medical costs (p<0.001), although no differences were noted for overall pharmacy costs. Provision of the disease management programme was through an external vendor and cost $31,250 per month regardless of the number enrolled. Future research should seek to assess long-term clinical, humanistic and economic outcomes in this population and to develop methods that increase programme participation.

Original languageEnglish (US)
Pages (from-to)411-426
Number of pages16
JournalJournal of medical economics
Volume10
Issue number4
DOIs
StatePublished - Jan 1 2007

Keywords

  • Disease management
  • Medicaid
  • Pharmacoeconomics
  • Schizophrenia
  • United States

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Cost analysis of a disease management programme for adult Medicaid clients with schizophrenia'. Together they form a unique fingerprint.

Cite this